Malawi
Tuberculosis profile
| High HIV burden |
Population  2013 16 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.5 (0.51–2.5) 9.3 (3.1–16)
Mortality (HIV+TB only) 3.4 (2–5.1) 21 (12–31)
Prevalence  (includes HIV+TB) 22 (11–37) 135 (67–226)
Incidence  (includes HIV+TB) 26 (25–28) 156 (152–168)
Incidence (HIV+TB only) 15 (9.5–20) 92 (58–125)
Case detection, all forms (%) 70 (65–71)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.4 (0.1–1) 4.8 (3.2–6.9)
MDR-TB cases among notified pulmonary
TB cases
51 (13–130) 110 (72–160)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 6 817   669
Pulmonary, clinically diagnosed 5 985    
Extrapulmonary 4 308    
       
Total new and relapse 17 779    
Previously treated, excluding relapses 1 580    
Total cases notified 19 359    
Among 17 779 new and relapse cases:
1 827 (10%) cases aged under 15 years; male:female ratio: 1.2
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 100 (1%) 459 (20%) 884
Laboratory-confirmed RR-/MDR-TB cases     91
Patients started on MDR-TB treatment     21
TB/HIV 2013 Number (%)
TB patients with known HIV status 17 820 (92)
HIV-positive TB patients 9 998 (56)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 8 979 (90)
HIV-positive TB patients on antiretroviral therapy (ART) 8 777 (88)
HIV-positive people screened for TB 458 972  
HIV-positive people provided with IPT 99 728  
Treatment success rate (%)
New and relapse cases registered in 2012 82
Previously treated cases, excluding relapse, registered in 2012 57
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 69
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 1.5
Drug susceptibility testing (per 5 million population) 1.2
Sites performing Xpert MTB/RIF 33
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 5.7
% Funded domestically 50%
% Funded internationally 50%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-06 Data: www.who.int/tb/data